Neurocrine Biosciences (NBIX) Shares Outstanding (Diluted) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Shares Outstanding (Diluted) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Dil.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.48 Bn | 625.73 Bn | 17.26 Bn | 2.44 Bn |
| 2 | AbbVie | 442.74 Bn | 436.17 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 366.39 Bn | 359.25 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | 1.96 Bn |
| 5 | Pfizer | 158.80 Bn | 147.10 Bn | 10.94 Bn | 5.70 Bn |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn | 1.23 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 210.89 Mn |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | 208.22 Mn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 45.80 Mn |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 104.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 104.20 Mn |
| Mar 31, 2026 | 103.40 Mn |
| Dec 31, 2025 | 102.50 Mn |
| Sep 30, 2025 | 102.50 Mn |
| Jun 30, 2025 | 101.00 Mn |
| Mar 31, 2025 | 102.50 Mn |
| Dec 31, 2024 | 103.70 Mn |
| Sep 30, 2024 | 104.30 Mn |
| Jun 30, 2024 | 103.90 Mn |
| Mar 31, 2024 | 103.60 Mn |
| Dec 31, 2023 | 101.00 Mn |
| Sep 30, 2023 | 101.10 Mn |
| Jun 30, 2023 | 100.20 Mn |
| Mar 31, 2023 | 97.10 Mn |
| Dec 31, 2022 | 98.90 Mn |
| Sep 30, 2022 | 99.00 Mn |
| Jun 30, 2022 | 95.60 Mn |
| Mar 31, 2022 | 97.60 Mn |
| Dec 31, 2021 | 97.90 Mn |
| Sep 30, 2021 | 97.70 Mn |